NCT06652633
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Recruiting
PHASE3Ages 18+InterventionalLakefront Biotherapeutics NV
~546 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:GLPG CAR T-cell therapy
At a glance
Recruiting sites
11 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants with targeted adverse events (AEs)
Measured over From infusion up to 15 years
+5 more outcomes measured
Conditions
Where it's being run
11 sites across 5 statesBelgium5
Netherlands3
Massachusetts1
Finland1
Spain1
Study leadership
- Lakefront Biotherapeutics Study Director · STUDY_DIRECTOR · Lakefront Biotherapeutics NV
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
All participants who have been treated with a Galapagos CAR T-cell therapy in a clinical trial or Managed Access Program.
What this trial measures
- Percentage of participants with targeted adverse events (AEs)From infusion up to 15 years
- Percentage of participants with detectable CAR transgene levels in peripheral bloodFrom infusion up to 15 years
- Percentage of participants with serious AEs (SAEs) considered related to the Galapagos CAR T-cell therapyFrom infusion up to 15 years
- Percentage of participants with at least 1% of T-cells in the blood sample or positive new malignanciesFrom infusion up to 15 years
- Percentage of participants with detectable replication-competent lentivirus (RCL) in peripheral bloodFrom infusion up to 15 years
- Percentage of participants who died with causesFrom infusion up to 15 years